Date: 2018-04-04
Type of information: Nomination
Compound: member of the board of directors
Company: Avrobio (USA - MA)
Therapeutic area: Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 4, 2018, Avrobio announced the appointment of Annalisa Jenkins, MBBS, FRCP, to its Board of Directors. Dr. Jenkins brings a wealth of expertise in advancing drug programs through clinical development and regulatory approval, including roles as the former head of Global R&D for Merck Serono and Head of Global Medical Affairs for BMS. She also has recent experience in the fields of gene therapy and rare diseases, having served as the CEO of Dimension Therapeutics, until its acquisition in late 2017. Dr. Jenkins will join as an independent director of Avrobio effective immediately.
- Currently, Dr. Jenkins chairs the boards of CellMedica, Cocoon, Vium, and Silence Therapeutics; serves as chief executive advisor to PlaqueTec; and is a director on the boards of Ardelyx, Oncimmune Holdings and a number of early-stage private biotech and life science companies. She also serves as a committee member of the Science Board to the FDA.
Financial terms:
Latest news:
Is general: Yes
